Andrew W Roberts

List of Publications by Year in Descending Order

231 papers	19,925 citations	68 h-index	139 g-index
238 ext. papers	22,925 ext. citations	7.8 avg, IF	6.35 L-index

#	Paper	IF	Citations
231	Comprehensive characterization of single-cell full-length isoforms in human and mouse with long-read sequencing. *Genome Biology*, **2021**, 22, 310	18.3	10
230	Pooled safety analysis of zanubrutinib monotherapy in patients with B-cell malignancies. *Blood Advances*, **2021**,	7.8	6
229	Addition of rituximab in relapsed/refractory chronic lymphocytic leukemia after progression on venetoclax monotherapy. *EJHaem*, **2021**, 2, 266-271	0.9	3
228	Intact TP-53 function is essential for sustaining durable responses to BH3-mimetic drugs in leukemias. *Blood*, **2021**, 137, 2721-2735	2.2	14
227	Efficacy of venetoclax plus rituximab for relapsed CLL: 5-year follow-up of continuous or limited-duration therapy. *Blood*, **2021**, 138, 836-846	2.2	6
226	Long-term Follow-up of Patients with Relapsed or Refractory Non-Hodgkin Lymphoma Treated with Venetoclax in a Phase I, First-in-Human Study. *Clinical Cancer Research*, **2021**, 27, 4690-4695	12.9	4
225	BCL2 and MCL1 inhibitors for hematologic malignancies. *Blood*, **2021**, 138, 1120-1136	2.2	7
224	Introduction to a review series on small-molecule targeted therapies for lymphoid malignancies. *Blood*, **2021**, 138, 1089	2.2	
223	Cereblon pathway biomarkers and immune profiles in patients with myeloma receiving post-ASCT lenalidomide maintenance (LEOPARD). *Leukemia and Lymphoma*, **2021**, 62, 2981-2991	1.9	0
222	Outcomes of patients with CLL sequentially resistant to both BCL2 and BTK inhibition. *Blood Advances*, **2021**, 5, 4054-4058	7.8	9
221	Cotargeting BCL-2 and MCL-1 in high-risk B-ALL. *Blood Advances*, **2020**, 4, 2762-2767	7.8	14
220	Targeting MCL-1 in hematologic malignancies: Rationale and progress. *Blood Reviews*, **2020**, 44, 100672	11.1	57
219	Deep profiling of apoptotic pathways with mass cytometry identifies a synergistic drug combination for killing myeloma cells. *Cell Death and Differentiation*, **2020**, 27, 2217-2233	12.7	18
218	High Clonal Complexity of Resistance Mechanisms Occurring at Progression after Single-Agent Targeted Therapy Strategies in Chronic Lymphocytic Leukemia. *Blood*, **2020**, 136, 15-16	2.2	0
217	Acquired Mutations in BAX Confer Resistance to BH3 Mimetics in Acute Myeloid Leukemia. *Blood*, **2020**, 136, 7-8	2.2	5
216	BAX-Mutated Clonal Hematopoiesis in Patients on Long-Term Venetoclax for Relapsed/Refractory Chronic Lymphocytic Leukemia. *Blood*, **2020**, 136, 9-10	2.2	2
215	The Impact of Sorafenib on Phospho-FLT3 Inhibition and FLT3-ITD MRD after Chemotherapy: Correlative Studies from the Phase 2 Randomized Study of Sorafenib Versus Placebo in Combination with Intensive Chemotherapy in Previously Untreated Patients with FLT3-ITD Acute Myeloid Leukemia (ALLG AMLM16). *Blood*, **2020**, 136, 16-18	2.2	1

214	BTK inhibitor therapy is effective in patients with CLL resistant to venetoclax. *Blood*, **2020**, 135, 2266-2270	20	35
213	Ptpn6 inhibits caspase-8- and Ripk3/Mlkl-dependent inflammation. *Nature Immunology*, **2020**, 21, 54-64	19.1	16
212	Potent efficacy of MCL-1 inhibitor-based therapies in preclinical models of mantle cell lymphoma. *Oncogene*, **2020**, 39, 2009-2023	9.2	12
211	Immune recovery in patients with mantle cell lymphoma receiving long-term ibrutinib and venetoclax combination therapy. *Blood Advances*, **2020**, 4, 4849-4859	7.8	6
210	Chemotherapy and Venetoclax in Elderly Acute Myeloid Leukemia Trial (CAVEAT): A Phase Ib Dose-Escalation Study of Venetoclax Combined With Modified Intensive Chemotherapy. *Journal of Clinical Oncology*, **2020**, 38, 3506-3517	2.2	43
209	Therapeutic development and current uses of BCL-2 inhibition. *Hematology American Society of Hematology Education Program*, **2020**, 2020, 1-9	3.1	17
208	Zanubrutinib for the treatment of patients with Waldenstrm macroglobulinemia: 3 years of follow-up. *Blood*, **2020**, 136, 2027-2037	2.2	33
207	Differential effects of BTK inhibitors ibrutinib and zanubrutinib on NK-cell effector function in patients with mantle cell lymphoma. *Haematologica*, **2020**, 105, e76-e79	6.6	26
206	Multiple BCL2 mutations cooccurring with Gly101Val emerge in chronic lymphocytic leukemia progression on venetoclax. *Blood*, **2020**, 135, 773-777	2.2	55
205	Undetectable peripheral blood MRD should be the goal of venetoclax in CLL, but attainment plateaus after 24 months. *Blood Advances*, **2020**, 4, 165-173	7.8	17
204	Characterization of a novel venetoclax resistance mutation (BCL2 Phe104Ile) observed in follicular lymphoma. *British Journal of Haematology*, **2019**, 186, e188-e191	4.5	24
203	Structures of BCL-2 in complex with venetoclax reveal the molecular basis of resistance mutations. *Nature Communications*, **2019**, 10, 2385	17.4	84
202	Efficacy of venetoclax in relapsed chronic lymphocytic leukemia is influenced by disease and response variables. *Blood*, **2019**, 134, 111-122	2.2	94
201	Polyclonal Heterogeneity: The New Norm for Secondary Clinical Resistance to Targeted Monotherapy in Relapsed Leukemia?. *Cancer Discovery*, **2019**, 9, 998-1000	24.4	4
200	Phase 1 study of the selective BTK inhibitor zanubrutinib in B-cell malignancies and safety and efficacy evaluation in CLL. *Blood*, **2019**, 134, 851-859	2.2	151
199	Venetoclax in Lymphoid Malignancies: New Insights, More to Learn. *Cancer Cell*, **2019**, 36, 341-343	24.3	12
198	A Phase 1, First-in-Human Study of AMG 176, a Selective MCL-1 Inhibitor, in Patients With Relapsed or Refractory Multiple Myeloma. *Clinical Lymphoma, Myeloma and Leukemia*, **2019**, 19, e53-e54	2	7
197	BTK Leu528Trp - a Potential Secondary Resistance Mechanism Specific for Patients with Chronic Lymphocytic Leukemia Treated with the Next Generation BTK Inhibitor Zanubrutinib. *Blood*, **2019**, 134, 170-170	2.2	12

196	Three Year Update of the Phase II ABT-199 (Venetoclax) and Ibrutinib in Mantle Cell Lymphoma (AIM) Study. *Blood*, **2019**, 134, 756-756	2.2	15
195	Anti-Leukemic Activity of Single Agent Venetoclax in Newly Diagnosed Acute Myeloid Leukemia: A Sub-Set Analysis of the Caveat Study. *Blood*, **2019**, 134, 462-462	2.2	3
194	Safety and Efficacy of Ibrutinib in Combination with Venetoclax in Patients with Marginal Zone Lymphoma: Preliminary Results from an Open Label, Phase II Study. *Blood*, **2019**, 134, 3999-3999	2.2	2
193	Venetoclax for the treatment of mantle cell lymphoma. *Annals of Lymphoma*, **2019**, 3, 4-4	1.8	0
192	Combining BH3-mimetics to target both BCL-2 and MCL1 has potent activity in pre-clinical models of acute myeloid leukemia. *Leukemia*, **2019**, 33, 905-917	10.7	84
191	A Phase Ib Dose-Escalation and Expansion Study of the BCL2 Inhibitor Venetoclax Combined with Tamoxifen in ER and BCL2-Positive Metastatic Breast Cancer. *Cancer Discovery*, **2019**, 9, 354-369	24.4	60
190	Dynamic molecular monitoring reveals that SWI-SNF mutations mediate resistance to ibrutinib plus venetoclax in mantle cell lymphoma. *Nature Medicine*, **2019**, 25, 119-129	50.5	94
189	Acquisition of the Recurrent Gly101Val Mutation in BCL2 Confers Resistance to Venetoclax in Patients with Progressive Chronic Lymphocytic Leukemia. *Cancer Discovery*, **2019**, 9, 342-353	24.4	188
188	Exploring the feasibility and utility of exome-scale tumour sequencing in a clinical setting. *Internal Medicine Journal*, **2018**, 48, 786-794	1.6	3
187	Long-term efficacy and safety of momelotinib, a JAK1 and JAK2 inhibitor, for the treatment of myelofibrosis. *Leukemia*, **2018**, 32, 1035-1038	10.7	35
186	Ibrutinib plus Venetoclax for the Treatment of Mantle-Cell Lymphoma. *New England Journal of Medicine*, **2018**, 378, 1211-1223	59.2	226
185	Enhancing venetoclax activity in acute myeloid leukemia by co-targeting MCL1. *Leukemia*, **2018**, 32, 303-312	10.7	96
184	MBD4 guards against methylation damage and germ line deficiency predisposes to clonal hematopoiesis and early-onset AML. *Blood*, **2018**, 132, 1526-1534	2.2	57
183	Statins enhance efficacy of venetoclax in blood cancers. *Science Translational Medicine*, **2018**, 10,	17.5	39
182	Comprehensive Safety Analysis of Venetoclax Monotherapy for Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia. *Clinical Cancer Research*, **2018**, 24, 4371-4379	12.9	90
181	Acquisition of the Recurrent Gly101Val Mutation in BCL2 Confers Resistance to Venetoclax in Patients with Progressive Chronic Lymphocytic Leukemia. *Blood*, **2018**, 132, LBA-7-LBA-7	2.2	3
180	Durability of Responses on Continuous Therapy and Following Drug Cessation in Deep Responders with Venetoclax and Rituximab. *Blood*, **2018**, 132, 183-183	2.2	5
179	Molecular Patterns of Response and Outcome in the Chemotherapy and Venetoclax in Elderly AML Trial (CAVEAT study). *Blood*, **2018**, 132, 333-333	2.2	11

178	Revised Dose Ramp-Up to Mitigate the Risk of Tumor Lysis Syndrome When Initiating Venetoclax in Patients With Mantle Cell Lymphoma. *Journal of Clinical Oncology*, **2018**, JCO1800359	2.2	12
177	Venetoclax for Patients With Chronic Lymphocytic Leukemia With 17p Deletion: Results From the Full Population of a Phase II Pivotal Trial. *Journal of Clinical Oncology*, **2018**, 36, 1973-1980	2.2	174
176	BH3-Mimetic Drugs: Blazing the Trail for New Cancer Medicines. *Cancer Cell*, **2018**, 34, 879-891	24.3	161
175	AMG 176, a Selective MCL1 Inhibitor, Is Effective in Hematologic Cancer Models Alone and in Combination with Established Therapies. *Cancer Discovery*, **2018**, 8, 1582-1597	24.4	194
174	BCL2 Inhibitors: Insights into Resistance. *Resistance To Targeted Anti-cancer Therapeutics*, **2018**, 23-43	0.3	
173	Treatment of patients with Waldenstrm macroglobulinaemia: clinical practice guidelines from the Myeloma Foundation of Australia Medical and Scientific Advisory Group. *Internal Medicine Journal*, **2017**, 47, 35-49	1.6	7
172	Venetoclax in Patients with Previously Treated Chronic Lymphocytic Leukemia. *Clinical Cancer Research*, **2017**, 23, 4527-4533	12.9	43
171	Venetoclax plus rituximab in relapsed or refractory chronic lymphocytic leukaemia: a phase 1b study. *Lancet Oncology, The*, **2017**, 18, 230-240	21.7	221
170	Clinicopathological features and outcomes of progression of CLL on the BCL2 inhibitor venetoclax. *Blood*, **2017**, 129, 3362-3370	2.2	114
169	Venetoclax: a primer. *Blood Advances*, **2017**, 1, 467	7.8	12
168	Phase I First-in-Human Study of Venetoclax in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma. *Journal of Clinical Oncology*, **2017**, 35, 826-833	2.2	442
167	Idarubicin Dose Escalation During Consolidation Therapy for Adult Acute Myeloid Leukemia. *Journal of Clinical Oncology*, **2017**, 35, 1678-1685	2.2	12
166	Promising efficacy and acceptable safety of venetoclax plus bortezomib and dexamethasone in relapsed/refractory MM. *Blood*, **2017**, 130, 2392-2400	2.2	182
165	Bisphosphonate guidelines for treatment and prevention of myeloma bone disease. *Internal Medicine Journal*, **2017**, 47, 938-951	1.6	13
164	Targeting BCL2 With BH3 Mimetics: Basic Science and Clinical Application of Venetoclax in Chronic Lymphocytic Leukemia and Related B Cell Malignancies. *Clinical Pharmacology and Therapeutics*, **2017**, 101, 89-98	6.1	74
163	Venetoclax responses of pediatric ALL xenografts reveal sensitivity of MLL-rearranged leukemia. *Blood*, **2016**, 128, 1382-95	2.2	100
162	The MCL1 inhibitor S63845 is tolerable and effective in diverse cancer models. *Nature*, **2016**, 538, 477-482	50.4	617
161	Targeting GM-CSF in inflammatory diseases. *Nature Reviews Rheumatology*, **2016**, 12, 37-48	8.1	160

160	Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia. *New England Journal of Medicine*, **2016**, 374, 311-22	59.2	1164
159	BET inhibition represses miR17-92 to drive BIM-initiated apoptosis of normal and transformed hematopoietic cells. *Leukemia*, **2016**, 30, 1531-41	10.7	22
158	Progress in BCL2 inhibition for patients with chronic lymphocytic leukemia. *Seminars in Oncology*, **2016**, 43, 274-9	5.5	15
157	Current challenges and novel treatment strategies in double hit lymphomas. *Therapeutic Advances in Hematology*, **2016**, 7, 52-64	5.7	19
156	Detailed Safety Analysis of Venetoclax Combined with Rituximab in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia. *Blood*, **2016**, 128, 2033-2033	2.2	4
155	Pooled Multi-Trial Analysis of Venetoclax Efficacy in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia. *Blood*, **2016**, 128, 3230-3230	2.2	11
154	Safety Profile of Venetoclax Monotherapy in Patients with Chronic Lymphocytic Leukemia. *Blood*, **2016**, 128, 4395-4395	2.2	6
153	Venetoclax Combined with Bortezomib and Dexamethasone for Patients with Relapsed/Refractory Multiple Myeloma. *Blood*, **2016**, 128, 975-975	2.2	18
152	Increased Idarubicin Dosage during Consolidation Therapy for Adult Acute Myeloid Leukemia Improves Leukemia-Free Survival. *Blood*, **2016**, 128, 338-338	2.2	
151	Rapid Inflammation in Mice Lacking Both SOCS1 and SOCS3 in Hematopoietic Cells. *PLoS ONE*, **2016**, 11, e0162111	3.7	19
150	Nephrotic syndrome as a complication of chronic graft-versus-host disease after allogeneic haemopoietic stem cell transplantation. *Internal Medicine Journal*, **2016**, 46, 737-41	1.6	8
149	Venetoclax in relapsed or refractory chronic lymphocytic leukaemia with 17p deletion: a multicentre, open-label, phase 2 study. *Lancet Oncology, The*, **2016**, 17, 768-778	21.7	536
148	The BCL2 selective inhibitor venetoclax induces rapid onset apoptosis of CLL cells in patients via a TP53-independent mechanism. *Blood*, **2016**, 127, 3215-24	2.2	181
147	Hierarchy for targeting prosurvival BCL2 family proteins in multiple myeloma: pivotal role of MCL1. *Blood*, **2016**, 128, 1834-1844	2.2	105
146	Targeting BCL-2-like Proteins to Kill Cancer Cells. *Trends in Cancer*, **2016**, 2, 443-460	12.5	88
145	Targeting apoptotic pathways to treat lymphoid malignancies. *Rinsho Ketsueki/the Japanese Journal of Clinical Hematology*, **2016**, 57, 2054-2058	1.8	1
144	Management of systemic AL amyloidosis: recommendations of the Myeloma Foundation of Australia Medical and Scientific Advisory Group. *Internal Medicine Journal*, **2015**, 45, 371-82	1.6	13
143	Cellular Mechanisms Underlying Complete Hematological Response of Chronic Myeloid Leukemia to BRAF and MEK1/2 Inhibition in a Patient with Concomitant Metastatic Melanoma. *Clinical Cancer Research*, **2015**, 21, 5222-34	12.9	4

142	Treatment of patients with multiple myeloma who are not eligible for stem cell transplantation: position statement of the myeloma foundation of Australia Medical and Scientific Advisory Group. *Internal Medicine Journal*, **2015**, 45, 335-43	1.6	4
141	Phase 1 study of the safety, pharmacokinetics, and antitumour activity of the BCL2 inhibitor navitoclax in combination with rituximab in patients with relapsed or refractory CD20+ lymphoid malignancies. *British Journal of Haematology*, **2015**, 170, 669-78	4.5	69
140	A Phase 1 study of the safety, pharmacokinetics and anti-leukemic activity of the anti-CD123 monoclonal antibody CSL360 in relapsed, refractory or high-risk acute myeloid leukemia. *Leukemia and Lymphoma*, **2015**, 56, 1406-15	1.9	90
139	Fas regulates neutrophil lifespan during viral and bacterial infection. *Journal of Leukocyte Biology*, **2015**, 97, 321-6	6.5	24
138	Results of a phase 2 study of pacritinib (SB1518), a JAK2/JAK2(V617F) inhibitor, in patients with myelofibrosis. *Blood*, **2015**, 125, 2649-55	2.2	89
137	Validating the allogeneic stem cell transplantation disease risk index: sample size, follow-up, and local data are important. *Transplantation*, **2015**, 99, 128-32	1.8	10
136	Aberrant actin depolymerization triggers the pyrin inflammasome and autoinflammatory disease that is dependent on IL-18, not IL-1*Journal of Experimental Medicine*, **2015**, 212, 927-38	16.6	97
135	BCL2 inhibition in double hit lymphoma. *Leukemia and Lymphoma*, **2015**, 56, 1928-9	1.9	1
134	Donald Metcalf (1929-2014). *Cell*, **2015**, 160, 361-2	56.2	2
133	Treatment of patients with multiple myeloma who are eligible for stem cell transplantation: position statement of the Myeloma Foundation of Australia Medical and Scientific Advisory Group. *Internal Medicine Journal*, **2015**, 45, 94-105	1.6	10
132	A Phase 1 Study of Venetoclax (ABT-199 / GDC-0199) Monotherapy in Patients with Relapsed/Refractory Non-Hodgkin Lymphoma. *Blood*, **2015**, 126, 254-254	2.2	58
131	Favorable Patient Survival after Failure of Venetoclax (ABT-199/ GDC-0199) Therapy for Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL). *Blood*, **2015**, 126, 2939-2939	2.2	10
130	Safety and Efficacy of Venetoclax (ABT-199/GDC-0199) in Combination with Bortezomib and Dexamethasone in Relapsed/Refractory Multiple Myeloma: Phase 1b Results. *Blood*, **2015**, 126, 3038-3038	2.2	15
129	Deep and Durable Responses Following Venetoclax (ABT-199 / GDC-0199) Combined with Rituximab in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia: Results from a Phase 1b Study. *Blood*, **2015**, 126, 830-830	2.2	33
128	The BTK Inhibitor, Bgb-3111, Is Safe, Tolerable, and Highly Active in Patients with Relapsed/ Refractory B-Cell Malignancies: Initial Report of a Phase 1 First-in-Human Trial. *Blood*, **2015**, 126, 832-832	2.2	79
127	Venetoclax (ABT-199/GDC-0199) Monotherapy Induces Deep Remissions, Including Complete Remission and Undetectable MRD, in Ultra-High Risk Relapsed/Refractory Chronic Lymphocytic Leukemia with 17p Deletion: Results of the Pivotal International Phase 2 Study. *Blood*, **2015**, 126, LBA-6-LBA-6	2.2	11
126	Aberrant actin depolymerization triggers the pyrin inflammasome and autoinflammatory disease that is dependent on IL-18, not IL-1*Journal of Cell Biology*, **2015**, 209, 2095OIA104	7.3	
125	RIPK1 regulates RIPK3-MLKL-driven systemic inflammation and emergency hematopoiesis. *Cell*, **2014**, 157, 1175-88	56.2	400

124	Targeting of acute myeloid leukemia in vitro and in vivo with an anti-CD123 mAb engineered for optimal ADCC. *Leukemia*, **2014**, 28, 2213-21	10.7	106
123	Both leukaemic and normal peripheral B lymphoid cells are highly sensitive to the selective pharmacological inhibition of prosurvival Bcl-2 with ABT-199. *Leukemia*, **2014**, 28, 1207-15	10.7	69
122	Thalidomide and prednisolone versus prednisolone alone as consolidation therapy after autologous stem-cell transplantation in patients with newly diagnosed multiple myeloma: final analysis of the ALLG MM6 multicentre, open-label, randomised phase 3 study. *Lancet Haematology,the*, **2014**, 1, e112-9	14.6	8
121	Targeting BCL2 for the treatment of lymphoid malignancies. *Seminars in Hematology*, **2014**, 51, 219-27	4	112
120	First-in Man, Phase 1 Study of CSL362 (Anti-IL3Rα/ Anti-CD123 Monoclonal Antibody) in Patients with CD123+ Acute Myeloid Leukemia (AML) in CR at High Risk for Early Relapse. *Blood*, **2014**, 124, 120-120	2.2	40
119	Determination of Recommended Phase 2 Dose of ABT-199 (GDC-0199) Combined with Rituximab (R) in Patients with Relapsed / Refractory (R/R) Chronic Lymphocytic Leukemia (CLL). *Blood*, **2014**, 124, 325-325	2.2	28
118	Leopard: A Phase II Study of Maintenance Lenalidomide and Prednisolone Post Autologous Stem Cell Transplantation (ASCT) for Myeloma, Incorporating Minimal Residual Disease Assessments. *Blood*, **2014**, 124, 2103-2103	2.2	
117	ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets. *Nature Medicine*, **2013**, 19, 202-8	50.5	1922
116	BH3 mimetic therapy: an emerging and promising approach to treating chronic lymphocytic leukemia. *Leukemia and Lymphoma*, **2013**, 54, 909-11	1.9	2
115	GFI1B mutation causes a bleeding disorder with abnormal platelet function. *Journal of Thrombosis and Haemostasis*, **2013**, 11, 2039-47	15.4	76
114	Proapoptotic Bak and Bax guard against fatal systemic and organ-specific autoimmune disease. *Proceedings of the National Academy of Sciences of the United States of America*, **2013**, 110, 2599-604	11.5	37
113	The genomic landscape of hypodiploid acute lymphoblastic leukemia. *Nature Genetics*, **2013**, 45, 242-52	36.3	474
112	Low adhesion receptor levels on circulating platelets in patients with lymphoproliferative diseases before receiving Navitoclax (ABT-263). *Blood*, **2013**, 121, 1479-81	2.2	19
111	Update On The Long-Term Efficacy and Safety Of Momelotinib, a JAK1 and JAK2 Inhibitor, For The Treatment Of Myelofibrosis. *Blood*, **2013**, 122, 108-108	2.2	30
110	Selective Bcl-2 Inhibition With ABT-199 Is Highly Active Against Chronic Lymphocytic Leukemia (CLL) Irrespective Of TP53 Mutation Or Dysfunction. *Blood*, **2013**, 122, 1304-1304	2.2	8
109	The Single-Agent Bcl-2 Inhibitor ABT-199 (GDC-0199) In Patients With Relapsed/Refractory (R/R) Non-Hodgkin Lymphoma (NHL): Responses Observed In All Mantle Cell Lymphoma (MCL) Patients. *Blood*, **2013**, 122, 1789-1789	2.2	22
108	Thalidomide Consolidation Post Autologous Stem Cell Transplant (ASCT) For Multiple Myeloma (MM) Is Cost-Effective With Durable Survival Benefit At 5 Years Post Randomisation: Final Analysis Of The ALLG MM6 Study. *Blood*, **2013**, 122, 537-537	2.2	5
107	Necroptotic Death Of RIPK1-Deficient HSC Compromises Hematopoiesis. *Blood*, **2013**, 122, 218-218	2.2	

106	Single-Centre Validation Of a Disease Risk Index For Estimating Survival and Relapse In Allogeneic Hematopoietic Stem Cell Transplant Recipients: Sample Size, Adequate Follow-Up, and Use Of Local Data Are Vital Considerations. *Blood*, **2013**, 122, 2143-2143	2.2	
105	Mcl-1 and Bcl-x(L) coordinately regulate megakaryocyte survival. *Blood*, **2012**, 119, 5850-8	2.2	63
104	IL-6 promotes acute and chronic inflammatory disease in the absence of SOCS3. *Immunology and Cell Biology*, **2012**, 90, 124-9	5	34
103	Bcl-2, Bcl-x(L), and Bcl-w are not equivalent targets of ABT-737 and navitoclax (ABT-263) in lymphoid and leukemic cells. *Blood*, **2012**, 119, 5807-16	2.2	150
102	Substantial susceptibility of chronic lymphocytic leukemia to BCL2 inhibition: results of a phase I study of navitoclax in patients with relapsed or refractory disease. *Journal of Clinical Oncology*, **2012**, 30, 488-96	2.2	622
101	Towards a four-dimensional view of neutrophils. *Methods in Molecular Biology*, **2012**, 844, 87-99	1.4	5
100	The equivalents of human blood and spleen dendritic cell subtypes can be generated in vitro from human CD34(+) stem cells in the presence of fms-like tyrosine kinase 3 ligand and thrombopoietin. *Cellular and Molecular Immunology*, **2012**, 9, 446-54	15.4	46
99	Translation inhibitors induce cell death by multiple mechanisms and Mcl-1 reduction is only a minor contributor. *Cell Death and Disease*, **2012**, 3, e409	9.8	36
98	Phase I/II Study of CYT387, a JAK1/JAK2 Inhibitor for the Treatment of Myelofibrosis. *Blood*, **2012**, 120, 178-178	2.2	7
97	The BCL-2-Specific BH3-Mimetic ABT-199 (GDC-0199) Is Active and Well-Tolerated in Patients with Relapsed Non-Hodgkin Lymphoma: Interim Results of a Phase I Study. *Blood*, **2012**, 120, 304-304	2.2	17
96	The BCL-2-Specific BH3-Mimetic ABT-199 (GDC-0199) Is Active and Well-Tolerated in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia: Interim Results of a Phase I First-in-Human Study. *Blood*, **2012**, 120, 3923-3923	2.2	3
95	Bcl-xL-inhibitory BH3 mimetics can induce a transient thrombocytopathy that undermines the hemostatic function of platelets. *Blood*, **2011**, 118, 1663-74	2.2	199
94	Overcoming blocks in apoptosis with BH3-mimetic therapy in haematological malignancies. *Pathology*, **2011**, 43, 525-35	1.6	33
93	Megakaryocytes possess a functional intrinsic apoptosis pathway that must be restrained to survive and produce platelets. *Journal of Experimental Medicine*, **2011**, 208, 2017-31	16.6	139
92	Fas-mediated neutrophil apoptosis is accelerated by Bid, Bak, and Bax and inhibited by Bcl-2 and Mcl-1. *Proceedings of the National Academy of Sciences of the United States of America*, **2011**, 108, 13135-40	11.5	79
91	Neutrophils require SHP1 to regulate IL-1β production and prevent inflammatory skin disease. *Journal of Immunology*, **2011**, 186, 1131-9	5.3	36
90	Results of a Phase 2 Study of Pacritinib (SB1518), a Novel Oral JAK2 Inhibitor, In Patients with Primary, Post-Polycythemia Vera, and Post-Essential Thrombocythemia Myelofibrosis. *Blood*, **2011**, 118, 282-282	2.2	14
89	An Expanded Multicenter Phase I/II Study of CYT387, a JAK- 1/2 Inhibitor for the Treatment of Myelofibrosis,. *Blood*, **2011**, 118, 3849-3849	2.2	10

88	Megakaryocytes possess a functional intrinsic apoptosis pathway that must be restrained to survive and produce platelets. *Journal of Cell Biology*, **2011**, 194, i12-i12	7.3	
87	Improved survival for relapsed diffuse large B cell lymphoma is predicted by a negative pre-transplant FDG-PET scan following salvage chemotherapy. *British Journal of Haematology*, **2010**, 150, 39-45	4.5	62
86	Regulation of interleukin-1beta by interferon-gamma is species specific, limited by suppressor of cytokine signalling 1 and influences interleukin-17 production. *EMBO Reports*, **2010**, 11, 640-6	6.5	55
85	The Bcl-2 homology domain 3 mimetic ABT-737 targets the apoptotic machinery in acute lymphoblastic leukemia resulting in synergistic in vitro and in vivo interactions with established drugs. *Molecular Pharmacology*, **2010**, 77, 483-94	4.3	102
84	Deficiency of 5-hydroxyisourate hydrolase causes hepatomegaly and hepatocellular carcinoma in mice. *Proceedings of the National Academy of Sciences of the United States of America*, **2010**, 107, 16625-30	11.5	24
83	Structural basis for apoptosis inhibition by Epstein-Barr virus BHRF1. *PLoS Pathogens*, **2010**, 6, e1001236	7.6	74
82	SOCS3 regulates graft-versus-host disease. *Blood*, **2010**, 116, 287-96	2.2	34
81	Navitoclax (ABT-263) Plus Rituximab: Interim Results of a Phase 1 Study In Patients with CD20-Positive Lymphoid Malignancies. *Blood*, **2010**, 116, 3943-3943	2.2	2
80	Reply to M. Cavo. *Journal of Clinical Oncology*, **2009**, 27, e188-e188	2.2	
79	Regulation of multiple cytokine signalling pathways by SOCS3 is independent of SOCS2. *Growth Factors*, **2009**, 27, 384-93	1.6	16
78	Clinical and immunohistochemical features associated with a response to bortezomib in patients with multiple myeloma. *Clinical Cancer Research*, **2009**, 15, 714-22	12.9	24
77	The BH3 mimetic compound, ABT-737, synergizes with a range of cytotoxic chemotherapy agents in chronic lymphocytic leukemia. *Leukemia*, **2009**, 23, 2034-41	10.7	84
76	Consolidation therapy with low-dose thalidomide and prednisolone prolongs the survival of multiple myeloma patients undergoing a single autologous stem-cell transplantation procedure. *Journal of Clinical Oncology*, **2009**, 27, 1788-93	2.2	278
75	BH3-mimetics--the solution to chemoresistance?. *Leukemia and Lymphoma*, **2009**, 50, 1069-72	1.9	4
74	Two distinct pathways regulate platelet phosphatidylserine exposure and procoagulant function. *Blood*, **2009**, 114, 663-6	2.2	240
73	Vascular endothelial growth factor inhibition is not an effective therapeutic strategy for relapsed or refractory multiple myeloma: a phase 2 study of pazopanib (GW786034). *Blood*, **2009**, 113, 4819-20	2.2	45
72	Cyclosporin, methotrexate and prednisolone for graft-versus-host disease prophylaxis in allogeneic peripheral blood progenitor cell transplants. *Bone Marrow Transplantation*, **2008**, 41, 651-8	4.4	12
71	Socs3 maintains the specificity of biological responses to cytokine signals during granulocyte and macrophage differentiation. *Experimental Hematology*, **2008**, 36, 786-98	3.1	21

70	Perturbed thymopoiesis in vitro in the absence of suppressor of cytokine signalling 1 and 3. *Molecular Immunology*, **2008**, 45, 2888-96	4.3	8
69	In vivo efficacy of the Bcl-2 antagonist ABT-737 against aggressive Myc-driven lymphomas. *Proceedings of the National Academy of Sciences of the United States of America*, **2008**, 105, 17961-6	11.5	124
68	Bortezomib: putting mantle cell lymphoma on death row. *Leukemia and Lymphoma*, **2008**, 49, 657-8	1.9	5
67	A key role for G-CSF-induced neutrophil production and trafficking during inflammatory arthritis. *Blood*, **2008**, 112, 5193-201	2.2	126
66	Complete Remission on 18F-FDG-PET Prior to Autologous Stem Cell Transplantation Predicts Superior Event Free Survival of Patients with Relapsed or Refractory Hodgkin Lymphoma.. *Blood*, **2008**, 112, 2188-2188	2.2	
65	Graft-versus-lymphoma effect in progressive hepatosplenic gamma/delta T-cell lymphoma. *Leukemia and Lymphoma*, **2007**, 48, 1448-50	1.9	13
64	A randomized comparison of empiric or pre-emptive antibiotic therapy after hematopoietic stem cell transplantation. *Bone Marrow Transplantation*, **2007**, 40, 157-63	4.4	28
63	The hyper-CVAD-rituximab chemotherapy programme followed by high-dose busulfan, melphalan and autologous stem cell transplantation produces excellent event-free survival in patients with previously untreated mantle cell lymphoma. *Annals of Hematology*, **2007**, 86, 101-5	3	59
62	Mechanism of crosstalk inhibition of IL-6 signaling in response to LPS and TNFalpha. *Growth Factors* , **2007**, 25, 319-28	1.6	12
61	Pathologic consequences of STAT3 hyperactivation by IL-6 and IL-11 during hematopoiesis and lymphopoiesis. *Blood*, **2007**, 109, 2380-8	2.2	57
60	The SOCS box of suppressor of cytokine signaling-3 contributes to the control of G-CSF responsiveness in vivo. *Blood*, **2007**, 110, 1466-74	2.2	52
59	A prospective multicenter trial of peripheral blood stem cell sibling allografts for acute myeloid leukemia in first complete remission using fludarabine-cyclophosphamide reduced intensity conditioning. *Biology of Blood and Marrow Transplantation*, **2007**, 13, 560-7	4.7	22
58	Programmed anuclear cell death delimits platelet life span. *Cell*, **2007**, 128, 1173-86	56.2	763
57	Improved Relapse Free Survival Is Predicted by a Negative Pre-Transplant FDG-PET Scan Following Salvage Chemotherapy for Relapsed Diffuse Large B Cell Lymphoma (DLBCL) Treated with Autologous Stem Cell Transplantation.. *Blood*, **2007**, 110, 5115-5115	2.2	
56	The BH3 mimetic ABT-737 targets selective Bcl-2 proteins and efficiently induces apoptosis via Bak/Bax if Mcl-1 is neutralized. *Cancer Cell*, **2006**, 10, 389-99	24.3	1049
55	Bim and Bad mediate imatinib-induced killing of Bcr/Abl+ leukemic cells, and resistance due to their loss is overcome by a BH3 mimetic. *Proceedings of the National Academy of Sciences of the United States of America*, **2006**, 103, 14907-12	11.5	291
54	Thrombocytopenia and kidney disease in mice with a mutation in the C1galt1 gene. *Proceedings of the National Academy of Sciences of the United States of America*, **2006**, 103, 16442-7	11.5	66
53	Granulocyte colony-stimulating factor and neutrophils--forgotten mediators of inflammatory disease. *Nature Clinical Practice Rheumatology*, **2006**, 2, 500-10		138

52	Allogeneic stem cell transplantation with peripheral blood stem cells mobilized by pegylated G-CSF. *Biology of Blood and Marrow Transplantation*, **2006**, 12, 603-7	4.7	32
51	Genetic heterogeneity of granulocytes for the JAK2 V617F mutation in essential thrombocythaemia: implications for mutation detection in peripheral blood. *Pathology*, **2006**, 38, 336-42	1.6	13
50	More on Myb in myelofibrosis: molecular analyses of MYB and EP300 in 55 patients with myeloproliferative disorders. *Blood*, **2006**, 107, 1733-5; author reply 1735	2.2	9
49	Reduced-intensity allogeneic haemopoietic stem cell transplantation induces durable responses in patients with chronic B-lymphoproliferative disorders. *Bone Marrow Transplantation*, **2006**, 37, 923-8	4.4	19
48	Absence of suppressor of cytokine signalling 3 reduces self-renewal and promotes differentiation in murine embryonic stem cells. *Stem Cells*, **2006**, 24, 604-14	5.8	45
47	SOCS-3 negatively regulates innate and adaptive immune mechanisms in acute IL-1-dependent inflammatory arthritis. *Journal of Clinical Investigation*, **2006**, 116, 1571-81	15.9	162
46	First Analysis of the Australasian Leukaemia and Lymphoma Group (ALLG) Trial of Thalidomide and Alternate Day Prednisolone Following Autologous Stem Cell Transplantation (ASCT) for Patients with Multiple Myeloma (ALLG MM6).. *Blood*, **2006**, 108, 58-58	2.2	20
45	G-CSF: a key regulator of neutrophil production, but that?s not all!. *Growth Factors*, **2005**, 23, 33-41	1.6	239
44	The threshold of gp130-dependent STAT3 signaling is critical for normal regulation of hematopoiesis. *Blood*, **2005**, 105, 3512-20	2.2	68
43	A multicenter phase II trial of thalidomide and celecoxib for patients with relapsed and refractory multiple myeloma. *Clinical Cancer Research*, **2005**, 11, 5504-14	12.9	45
42	Genetic reduction of embryonic leukemia-inhibitory factor production rescues placentation in SOCS3-null embryos but does not prevent inflammatory disease. *Proceedings of the National Academy of Sciences of the United States of America*, **2005**, 102, 16333-8	11.5	42
41	Allogeneic Stem Cell Transplantation with Peripheral Blood Stem Cells Mobilized by Pegylated-G-CSF.. *Blood*, **2005**, 106, 1970-1970	2.2	
40	A Pilot Study To Explore the Tolerability and Efficacy of Thalidomide Containing Regimens To Reduce Tumour Cell Load Prior to HSC in Multiple Myeloma and the Feasibility of Harvesting HSC Following Thalidomide Containing Regimens.. *Blood*, **2005**, 106, 5162-5162	2.2	
39	Suppressor screen in Mpl-/- mice: c-Myb mutation causes supraphysiological production of platelets in the absence of thrombopoietin signaling. *Proceedings of the National Academy of Sciences of the United States of America*, **2004**, 101, 6553-8	11.5	162
38	Critical role for granulocyte colony-stimulating factor in inflammatory arthritis. *Proceedings of the National Academy of Sciences of the United States of America*, **2004**, 101, 11398-403	11.5	94
37	Guidelines for the use of antifungal agents in the treatment of invasive Candida and mould infections. *Internal Medicine Journal*, **2004**, 34, 192-200	1.6	41
36	Staged autologous peripheral blood progenitor cell transplantation for Ewing sarcoma and rhabdomyosarcoma. *Internal Medicine Journal*, **2004**, 34, 431-4	1.6	6
35	A pilot study of targeted itraconazole prophylaxis in patients with graft-versus-host disease at high risk of invasive mould infections following allogeneic stem cell transplantation. *Bone Marrow Transplantation*, **2004**, 34, 447-53	4.4	19

34	SOCS3 is a critical physiological negative regulator of G-CSF signaling and emergency granulopoiesis. *Immunity*, **2004**, 20, 153-65	32.3	223
33	Pamidronate Therapy for One Year after Allogeneic Bone Marrow Transplantation (AlloBMT) Reduces Bone Loss from the Lumbar Spine, Femoral Neck and Total Hip.. *Blood*, **2004**, 104, 2253-2253	2.2	6
32	Tissue Iron Overload Is Common Post Transplantation (Allo BMT) and Is Associated with Red Cell Transfusion Load and HFE Genotype.. *Blood*, **2004**, 104, 2262-2262	2.2	
31	Morphological effects of imatinib mesylate (STI571) on the bone marrow and blood of patients with Philadelphia chromosome (Ph) positive chronic myeloid leukaemia. *International Journal of Laboratory Hematology*, **2003**, 25, 119-25		7
30	SOCS3 negatively regulates IL-6 signaling in vivo. *Nature Immunology*, **2003**, 4, 540-5	19.1	663
29	Graft-versus-host disease, donor chimerism, and organ toxicity in stem cell transplantation after conditioning with fludarabine and melphalan. *Biology of Blood and Marrow Transplantation*, **2003**, 9, 435-42	4.7	19
28	Hematopoietic abnormalities in mice deficient in gp130-mediated STAT signaling. *Experimental Hematology*, **2002**, 30, 1248-56	3.1	23
27	Mobilization of dendritic cells in cancer patients treated with granulocyte colony-stimulating factor and chemotherapy. *British Journal of Haematology*, **2002**, 119, 204-11	4.5	7
26	Rac2-deficient mice display perturbed T-cell distribution and chemotaxis, but only minor abnormalities in T(H)1 responses. *Immunology and Cell Biology*, **2002**, 80, 231-40	5	48
25	A phase I dose-escalation study of etoposide continuous infusion added to busulphan/cyclophosphamide as conditioning prior to autologous or allogeneic stem cell transplantation. *Bone Marrow Transplantation*, **2002**, 30, 645-50	4.4	8
24	Dok-related protein negatively regulates T cell development via its RasGTPase-activating protein and Nck docking sites. *Journal of Cell Biology*, **2002**, 158, 115-25	7.3	28
23	The Rac2 guanosine triphosphatase regulates B lymphocyte antigen receptor responses and chemotaxis and is required for establishment of B-1a and marginal zone B lymphocytes. *Journal of Immunology*, **2002**, 168, 3376-86	5.3	103
22	Successful allogeneic stem cell transplant after invasive pulmonary zygomycosis. *Leukemia and Lymphoma*, **2002**, 43, 437-9	1.9	14
21	Acute left ventricular failure following melphalan and fludarabine conditioning. *Bone Marrow Transplantation*, **2001**, 28, 101-3	4.4	46
20	Rac and Cdc42 GTPases control hematopoietic stem cell shape, adhesion, migration, and mobilization. *Proceedings of the National Academy of Sciences of the United States of America*, **2001**, 98, 5614-8	11.5	169
19	Placental defects and embryonic lethality in mice lacking suppressor of cytokine signaling 3. *Proceedings of the National Academy of Sciences of the United States of America*, **2001**, 98, 9324-9	11.5	266
18	Identification of a genetic locus modulating splenomegaly induced by granulocyte colony-stimulating factor in mice. *Leukemia*, **2000**, 14, 657-61	10.7	16
17	Role of the guanosine triphosphatase Rac2 in T helper 1 cell differentiation. *Science*, **2000**, 288, 2219-22	33.3	136

16	Mini-allografts for haematological malignancies: an alternative to conventional myeloablative marrow transplantation. *Australian and New Zealand Journal of Medicine*, **1999**, 29, 308-14		10
15	Deficiency of the hematopoietic cell-specific Rho family GTPase Rac2 is characterized by abnormalities in neutrophil function and host defense. *Immunity*, **1999**, 10, 183-96	32.3	474
14	Cytokine Production and Function in c-mpl Deficient Mice: No Physiologic Role for Interleukin-3 in Residual Megakaryocyte and Platelet Production. *Blood*, **1998**, 91, 2745-2752	2.2	60
13	Hematopoietic stem cell deficiencies in mice lacking c-Mpl, the receptor for thrombopoietin. *Proceedings of the National Academy of Sciences of the United States of America*, **1998**, 95, 1195-200	11.5	303
12	Optimal regimens for the mobilization and collection of peripheral blood progenitor cells from normal donors. *Leukemia and Lymphoma*, **1997**, 27, 77-82	1.9	
11	Genetic Influences Determining Progenitor Cell Mobilization and Leukocytosis Induced by Granulocyte Colony-Stimulating Factor. *Blood*, **1997**, 89, 2736-2744	2.2	131
10	Mouse loci for malaria-induced mortality and the control of parasitaemia. *Nature Genetics*, **1997**, 17, 380-3	36.3	89
9	Studies of the c-Mpl thrombopoietin receptor through gene disruption and activation. *Stem Cells*, **1996**, 14 Suppl 1, 124-32	5.8	30
8	Abnormal neutrophil phenotype and neutrophil FcRIII deficiency corrected by bone marrow transplantation. *Transfusion*, **1995**, 35, 874-8	2.9	2
7	Broad inter-individual variations in circulating progenitor cell numbers induced by granulocyte colony-stimulating factor therapy. *Stem Cells*, **1995**, 13, 512-6	5.8	62
6	Phase II study of glycosylated recombinant human granulocyte colony-stimulating factor after HLA-identical sibling bone marrow transplantation. *Australian and New Zealand Journal of Medicine*, **1994**, 24, 541-6		4
5	Immune thrombocytopenia complicating pulmonary tuberculosis: case report and investigation of mechanisms. *Thorax*, **1992**, 47, 396-7	7.3	27
4	All-trans retinoic acid--chemotherapy interactions in acute promyelocytic leukaemia. *Australian and New Zealand Journal of Medicine*, **1992**, 22, 704		
3	The diagnosis of abdominal aortic aneurysms. *ANZ Journal of Surgery*, **1974**, 44, 360-2	1	1
2	Comprehensive characterization of single cell full-length isoforms in human and mouse with long-read sequencing		10
1	Germline loss-of-function variants in the base-excision repair gene MBD4 cause a Mendelian recessive syndrome of adenomatous colorectal polyposis and acute myeloid leukaemia		3